{"id":"W2729990002","doi":"10.1177/1753944717714921","title":"Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Cardiovascular Disease","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bayer (Canada); McMaster University","funders":"Bayer Canada","keywords":"Medicine; Edoxaban; Dabigatran; Apixaban; Rivaroxaban; Dosing; Renal function; Pharmacodynamics; Atrial fibrillation; Intensive care medicine; Internal medicine; Pharmacology; Pharmacokinetics; Warfarin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005519117,0.0006209582,0.003024174,0.0004122958,0.00009869402,0.00009812193,0.0002568906,0.0001419628,0.00002122937],"category_scores_gemma":[0.0000637329,0.0004312959,0.00165835,0.000300205,0.000172973,0.0004624218,0.0001206693,0.0003191024,0.00002676078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003314779,"about_ca_system_score_gemma":0.0002240405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003189737,"about_ca_topic_score_gemma":0.00001656847,"domain_scores_codex":[0.9967895,0.0003325057,0.000706824,0.0007670888,0.0009114685,0.0004926801],"domain_scores_gemma":[0.9977885,0.00008992348,0.0003166989,0.001502794,0.00006443464,0.0002375789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005294791,0.00008803874,0.1462723,0.004375566,0.001719085,0.000346255,0.000008799278,0.0001312206,3.620909e-9,0.00002233056,0.00000249275,0.8465044],"study_design_scores_gemma":[0.00437913,0.0001193276,0.1707873,0.006493047,0.005816075,0.000004063335,0.000004109518,0.00001904597,4.033595e-8,0.0000204438,0.8118933,0.0004640484],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006728211,0.9954352,0.000250346,0.00002000148,0.0002529256,0.003181861,0.00006071032,0.00004313024,0.00008303724],"genre_scores_gemma":[0.005564601,0.9931334,0.000193643,0.00003817982,0.0002539433,0.00005858977,0.0004861299,0.00009502937,0.0001765263],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8460404,"threshold_uncertainty_score":0.9998139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1014224525303861,"score_gpt":0.3760838915780124,"score_spread":0.2746614390476263,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}